---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-290725"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:03:45.296941+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma appoints Michael Kalb as CFO; Alicia Grande to retire at year-end 2023

## Summary
- Alicia Grande to retire as CFO at end of 2023; will remain as consultant through Dec 31, 2024.
- Michael W. Kalb appointed EVP & CFO effective Jan 1, 2024; base salary $525k, bonus up to 50%, equity grant $3M.
- Dr. Steven Miller promoted to EVP, Chief Operating & Scientific Officer; Jeffrey Del Carmen to EVP, Chief Commercial Officer.
- Kalb has 30+ years pharma/finance experience, previously CFO of Impel, CinCor, and Amarin.

## SEC filing metadata
- accession: 0001193125-23-290725
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/d418309d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-290725
- JSON: https://secwatch.observer/filing/0001193125-23-290725.json
- Plain text: https://secwatch.observer/filing/0001193125-23-290725.txt

## Key facts
- Executive change
  Michael W. Kalb was appointed as Executive Vice President and Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Executive Vice President and Chief Financial Officer
  source text: On December 4, 2023, the Company announced the appointment of Michael W. Kalb as the Company's Executive Vice President and CFO, effective January 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm
- Executive change
  Jeffrey Del Carmen changed role as Executive Vice President, Chief Commercial Officer at CATALYST PHARMACEUTICALS, INC..
  - Action: promoted
  - Role: Executive Vice President, Chief Commercial Officer
  source text: and of Jeffrey Del Carmen to Executive Vice President, Chief Commercial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm
- Executive change
  Alicia Grande retired as Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..
  - Action: retired
  - Role: Chief Financial Officer
  source text: On December 1, 2023, Alicia Grande, the Chief Financial Officer ("CFO") of Catalyst Pharmaceuticals, Inc. (the " Company ") informed the Company of her intent to retire as the Company's CFO at the end of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm
- Executive change
  Steven Miller changed role as Executive Vice President, Chief Operating and Scientific Officer at CATALYST PHARMACEUTICALS, INC..
  - Action: promoted
  - Role: Executive Vice President, Chief Operating and Scientific Officer
  source text: the Company reported the promotion, effective on January 1, 2024, of Dr. Steven Miller to Executive Vice President, Chief Operating and Scientific Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523290725/0001193125-23-290725-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.